INTRODUCTION
Increasing interest is now being shown in phobias in the elderly as they have been associated with higher mortality, increased proinflammatory cytokines 1, 2 and stress reactivity 3 , lower heart rate variability, 4 fatal coronary artery disease, and sudden cardiac death 5 . Recent studies of anxiety disorders in the elderly suggest that rates of all phobias may not only be much higher than previous epidemiological studies have suggested, but perhaps even constitute the most common form of anxiety disorder in this population 6 . Agoraphobia is a specific form of phobia which has been differentiated from other phobias within the international classifications of psychiatric disorder, principally due to its assumed association with panic attacks. It is defined as a fear and avoidance of being in places or situations from which escape might be difficult in the event of sudden incapacitation. As a result of such fears, the agoraphobic person avoids travel or requires a companion when away from home. Moderate cases may cause some constriction in lifestyle, while severe cases of agoraphobia may result in the person being completely housebound or unable to leave home unaccompanied. Within DSM-IV 7 agoraphobia is a sub-section of panic disorder.
Agoraphobia without a history of panic disorder may be classified as such, but is considered atypical.
Agoraphobia in the elderly has received little attention, being considered to be principally a disorder of young adulthood 2 ; the Epidemiological Catchment Area study in the U.S. for example reported a one month prevalence of agoraphobia in persons over 65 of under 1.4% 8 . Clinical reports have suggested, however, that this form of phobia is commonly overlooked in the elderly; unwillingness to go outside the home being easily attributed to poor health and loss of social networks 9 . Undetected agoraphobia in the elderly is highly unlikely to improve spontaneously 10 and given its association with anxiety and depressive symptoms, is likely to lead to a downward spiral of loneliness and deteriorating mental health. On the other hand, treatment of agoraphobia with cognitivebehavioural therapies and psychotropics has been proven to be highly successful at all ages 9, 11, 12 .
The aim of the present study is to provide estimates of the rates, clinical characteristics and risk factors for late-onset agoraphobia from a large prospective population study; previous studies being compromised by small samples, hierarchical case-finding procedures excluding cases with comorbidity, and failure to take into account potential confounding factors. The current study is part of a longitudinal project (the ESPRIT study) examining psychiatric disorder in the elderly using a standardized clinical interview based on international diagnostic algorithms for agoraphobia with clinical case validation. The study also has extensive information relating to clinical and life-style variables, permitting the identification of risk factors, and adjustment for multiple potential confounding factors.
METHOD

Sample
Community dwelling persons 65 years and over, were recruited by random selection from the fifteen electoral rolls of the Montpellier district between March 1999 and February 2001 as part of the ESPRIT study of late-life psychiatric disorder 13 . Of the persons contacted 72.7% accepted. Refusers were replaced by another subject drawn at random from the same electoral division such that each division is equally represented. Subjects refusing were slightly older and more likely to live alone than non-refusers. Participants were given a base-line examination and re-examined with a detailed psychiatric interview on two further occasions at intervals of two and four years. Seventy persons diagnosed with dementia at base-line were excluded from the present study. Dementia was diagnosed by a neurologist as part of a standardized examination (see below) and validated by a panel of independent neurologists. Of the 2189 dementia-free participants included in the ESPRIT study, 221 were excluded because of missing data on agoraphobia or on one of the main sociodemographic variables at baseline. The cross-sectional analyses were thus conducted on a maximum of 1968 persons. Participants did not differ from those excluded from the analysis for baseline sociodemographic and health variables. The longitudinal analysis was carried out on participants with either 2-year or 4-year follow-up examinations. Of the baseline sample, 98 participants (5%) were missing both follow-up examinations, (38 died, 26 were lost to follow-up and 34 refused to participate). Compared to the follow-up participants, those lost to follow-up were older (p=0.0004), with a lower educational level (p=0.02), with more frequent baseline respiratory problems (p<0.0001), cardio and cerebro-vascular pathologies (p=0.02), and disability (p<0.0001). There were no significant differences for baseline depressive symptomatology, anxiety or agoraphobia. Incident cases of dementia (n=48) were retained in the study as they were still community-dwelling and able to undertake the examinations. In cases of doubt family proxies and general practitioners were consulted. The study protocol was approved by the Ethics Committee of the University-Hospital of Kremlin-Bicêtre and written informed consent was obtained from each participant.
Measures
Participants were required to attend a half-day examination by a neurologist and a centre interviewer (nurse or psychologist) at the Gui de Chauliac Neurology Hospital (Montpellier, France).
Persons unable to come to the study centre (7% of participants) were examined in their homes. The following procedures were carried out:
A standardized health interview covering present and past health and medication use (subjects were asked to bring medications to the centre). The examination covered past and current vascular disease (angina pectoris, arrhythmia, lower limb arteritis, heart failure, myocardial infarction, cardiovascular surgery, stroke) and other chronic illnesses (cancer, osteoporosis, asthma, diabetes defi ed as fasti g glu ose≥ ol/l or treat e t, h per holesterole ia defi ed as total holesterol ≥ .
ol/l or treat e t, h perte sio defi ed as resti g lood pressure ≥ /9 Hg or treatment, and thyroid disorders).
Confinement (to bed, home or neighbourhood) for health reasons was noted and disability measured using the Rosow and Breslow mobility scale (ability to do heavy housework, walk over 500 metres and go up and down two flights of stairs) 14 . Scores were grouped into tertiles and the lowest compared to the highest two.
Childhood environment A retrospective self report questionnaire 24 examining traumatic experiences during childhood and adolescence and covering 25 adverse and 8 protective factors, was given to subjects for completion at the second follow-up.
Statistical Analysis
A sensitivity analysis was conducted to compare participants with those excluded using the Chi² test.
The Chi² test and Fisher exact test were used to compare crude rates for psychiatric co-morbidities at baseline and follow-up. The clinical characteristics of the sample of 1968 subjects is described according to presence or not of agoraphobia at baseline, giving p-values from a logistic regression analysis adjusted for age, sex and education. The incident rate over the follow-up was calculated on 1175 subjects with no baseline history of agoraphobia and data available at both follow-ups. For new cases the exact date of onset during the follow-up period was not available, onset was therefore considered to have occurred midway between the two examinations. 
RESULTS
In our population of community-dwelling adults 65 years and over, the base-line one-month prevalence of agoraphobia is observed to be 10.4%, with a life-time prevalence of 17.7%. Of these, 10.9% of cases were reported as having their onset over age 65. The sample, overall and according to baseline agoraphobia, is described in Table 1 . Agoraphobia is more frequent in women ( p<0.0001) and in lower educational levels (p=0.01). The mean (SD) age of cases is 72.3 (5.2) and for non-cases 72.8 (4.9) (non significant). Regarding other psychiatric conditions, agoraphobia is significantly associated with trait anxiety (p=0.0005), severe depressive symptomatology (p<0.0001) and a history of major depression (p=0.02). Table 1 here
Over the four-year follow-up 11.2% (132/1175) of the sample had a first episode of agoraphobia. The incidence rate is estimated at 32 per 1000 person-years. During the follow-up period these subjects also had more frequent first episodes of other anxiety disorders (11.5% in cases vs. 5.0% in noncases; Chi²=7.96; p=0.005), specifically general anxiety disorder (8.5% in cases vs. 4.5% in non-cases;
Chi²=3.43; p=0.06), and marginally more frequent suicidal ideation (13.3% in cases vs. 8.3% in noncases; Chi²=3.06; p=0.08). There was no increase compared to non-agoraphobic subjects in the incidence of severe depression (6.5% in cases vs.4.3% in non-cases; Fisher exact test F=0.11; p=0.29).
Only one new case of agoraphobia (0.8%) had panic disorder within the follow-up period and one reported previous panic disorder at baseline (0.8%). These rates were not significantly different to those found among non-cases.
In order to determine potential risk factors for agoraphobia onset in the elderly, a mixed regression model adjusted for age and time to diagnosis examined the association between socio-demographic and clinical characteristics at base-line and incident cases of agoraphobia at 2 and 4 year follow-up ( and education. This was also found to be non-significant (HR= 1.07 ; 95%CI 0.53-2.14 , p=0.85). 
DISCUSSION
Prevalence, incidence and co-morbidity
Our prospective study of agoraphobia in a large general population cohort using a standardized clinical interview based on DSM-IV criteria with clinical validation of cases, suggests the disorder to have a much higher prevalence in the elderly than was suggested by the 1988 ECA study (10.4% versus 1.4%). A subsequent study carried out in the U.K. using DSM III criteria 26 on a small sample of 168 elderly persons from a community care service found similarly high rates of agoraphobia (14.9%), which was lowered to 6.5% when hierarchical exclusion rules were applied. The exclusion rule includes co-morbid major depression, which if applied to our cohort would have more than halved the base-line prevalence estimate.
Over the four-year follow-up period we detected and validated 132 new cases of agoraphobia (11.2%
of the base-line population) without application of hierarchical decision rules, giving an estimated general population incidence of 32 per 1000 person-years. During follow-up these new cases were also seen to be associated with incidence of other anxiety disorders (principally generalized anxiety disorder) and suicidal ideation. Although agoraphobia was seen to be commonly preceded by depression, new cases of agoraphobia were not accompanied by incident depression, suggesting that depression is a risk factor, and not a consequence of agoraphobia.
The overall rates observed for panic disorder (less than 1%) are similar to those found by the National Co-morbidity Survey Replication
27
. The importance of panic attacks as a risk factor for agoraphobia in younger populations 28, 29 has led to an assumption that they are part of the same syndrome, largely based on the behavioral hypothesis that agoraphobia is a conditioned avoidance response to the aversive stimulus of spontaneous panic attacks. According to this model panic attacks are the primary diagnosis, although other investigators including the behavioral scientist although this has never been investigated in a prospective epidemiological study. Our findings support this observation, with only two of the 132 incident cases having a previous or recent episode of panic attacks, but having more than doubled the rates of depression found in non-agoraphobic persons at base-line. Overall, results fro the urre t stud largel support Fli t's 9 observation that depression is the primary co-pathology and that antidepressants and/or behavioral therapies, rather than benzodiazepines, should be the treatment of choice in elderly cases of agoraphobia. At baseline we found that only 6% of persons with agoraphobia were treated with an anti-depressant and 13% with an anxiolytic (results not shown). These rates were not significantly higher than for the non-agoraphobic group.
Risk factors
The principal documented risk factors for all phobias are younger age, female gender, living alone, physical illness, other anxiety disorders and depression, not having been raised by both parents, and cognitive disorder [31] [32] [33] [34] . All of these risk factors were examined in the present study. The odds of incident agoraphobia during follow-up were seen to decrease with age at baseline, whereas poorer visuospatial memory, high trait anxiety and severe depression at baseline were associated with increased odds. On the other hand we found no significant association with living alone, physical illness, or child-rearing conditions (data not shown). Interestingly, although a higher prevalence rate of agoraphobia was observed in women at base-line, the slightly greater number of women in new cases aged 65 and above did not quite reach significance, and disappeared in the multivariate risk model, probably due to confounding by depression and anxiety.
Boldrini et al. 35 found agoraphobia to be specifically associated with spatial learning impairment and our findings further support this observation, with agoraphobia onset being accompanied by poor performance on a visuospatial memory task but not a verbal fluency test. Poor visuospatial performance has been associated with falls and sensory impairment, which might have confounded the association, however, no association was found with either sensory impairment or falls.
It has previously been suggested 36 that a past history of any anxiety disorder doubles the probability of both suicidal ideation and suicide attempts. We observed higher rates of suicidal ideation in persons with agoraphobia at baseline (16.6% vs. 9.1% for non-cases). This observation was further confirmed prospectively, with new cases of agoraphobia being paralleled by an increase in the incidence of suicidal ideation. On the other hand, no association was found between onset of agoraphobia and base-line cardiac pathology. Nor were new cases accompanied by an increase in incidence of cardiac disorder in contrast to previous observations relating to phobic anxiety in general 5, 4 . Persons with reduced mobility were also found to be at greater risk, however, its significance disappears within a multivariate analysis taking into account competing risk factors.
A weakness of the study has been reliance on retrospective recall by participants of life events and previous episodes of agoraphobia. While the refusal rate is low for an epidemiological study we cannot exclude bias due to loss at both base-line and follow-up of a more disabled group, which along with our non-inclusion of institutionalized persons at base-line may have led to an underestimation of the actual number of cases. Depression and poor physical health are strongly associated in the elderly, and while we have eliminated confounding due to all the main causes of chronic and acute illness in this cohort we have not examined self-perceived health which may have had an independent effect. Furthermore, while we have demonstrated the significance of depression as a risk factor, the study design does not permit us to clarify the causal association between the two. Further research is required to clarify whether there may be a direct relationship based on underlying neurophysiological changes driven by chronic depressive symptomatology or whether the association is further moderated by complex interactions implicating genetic and biochemical vulnerability, social learning and cognitive processes. On the other hand the study has a number of strengths; incident case identification procedures have been rigorous and this well phenotyped study has been able to examine a large number of potential confounding factors within a prospective design. Overall our findings suggest that agoraphobia may be relatively common in the elderly, occurring in over 10% of community-dwelling persons. Late-onset cases show some clear distinctions from clinical reports of early onset cases. Firstly there seems to be no clear sex difference. While early onset cases have been more frequently associated with panic disorder, this appears not to be the case in late-onset cases, in which severe depression is predominant as a risk factor rather than a consequence of the disorder. The principal risk factors for late-onset agoraphobia are younger age, severe depression, trait anxiety and poor performance on a test of visuospatial memory. Unlike other phobias, there does not appear to be increased risk for cardiac pathology, although our four-year follow-up period may be too short to definitively conclude on this point. Agoraphobia in this cohort is clearly under-treated, with preference still being for anxiolytics rather than anti-depressants despite the presence of severe depressive symptoms. Screening for agoraphobia in the elderly is clearly worthwhile as it is a highly treatable condition which may be masked by depression, and overlooked due to lack of history of panic attacks. Its association in the elderly with suicidal ideation is of clinical concern, as persons with agoraphobia may be less likely to seek assistance. Our finding that agoraphobia in the elderly has a clinically atypical presentation in comparison with younger cases is also of relevance to the on-going process of revision of diagnostic criteria for psychiatric disorder, suggesting the need to consider the possibility of a syndrome sub-type in older populations.
Clinical Vignette
A 76 year-old married woman reported experiencing a depressive episode 10 years prior to interview following a traumatic event. At this time she received only symptomatic treatment for sleeping difficulties. She has subsequently experienced chronic depressive symptoms, notably periods of tearfulness and sleep disturbance but did not have major depressive disorder at the time of examination. She currently reports being unable to go out alone for fear of something happening to her, and is particularly fearful of empty streets, crowds and public transport. She is able to drive but will only do so if accompanied. She has no past history of panic disorder and no chronic or acute illnesses or disability. Her self-rated health is very good. At two year follow-up her fears had worsened and she rarely leaves the house as her husband is now disabled.
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